Preconception care for women with type 1 and type 2 diabetesdthe same but different

Canadian Journal of Diabetes

Volumn 36, Issue 2, 2012, Pages 83-86

  Keely, Erin ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Preconception counselling; Pregestational diabetes; Prepregnancy care

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

ARTICLE; CONGENITAL MALFORMATION; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; FEMALE; GLYCEMIC CONTROL; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MATERNAL CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COUNSELING; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; RECOMMENDED DRUG DOSE; RISK FACTOR;

EID: 84872412777     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2012.03.001     Document Type: Article

References (38)

1. Feig DS, Razzaq A, Sykora K, et al. Trends in deliveries, prenatal care, and obstetrical complications in women with pregestational diabetes: a population- based study in Ontario, Canada, 1996-2001. Diabetes Care 2006;29: 232e5.
2. The Confidential Enquiry into Maternal and Child Health (CEMACH). Diabetes in pregnancy: caring for the baby after birth. Findings of a national enquiry: England, Wales and Northern Ireland. CEMACH: London; 2007.
3. Murphy HR, Steel SA, Roland JM, et al. Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med 2011;28:1060e7.
4. Finer L, Henshaw S. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006;38:90e6.
5. Duranthon V, Watson AJ, Lonergan P. Preimplantation embryo programming: transcription, epigenetics, and culture environment. Reproduction 2008;135: 141e50.
6. Zabihi S, Loeken MR. Understanding diabetic teratogenesis: where are we now and where are we going?. Birth Defects Res A Clin Mol Teratol 2010;88:779e90.
7. Inkster ME, Fahey TP, Donnan PT, et al. Poor glycated haemoglobin control and adverse pregnancy outcomes in type1 and type 2 diabetes mellitus: systematic review of observational studies. BMC Pregnancy Childbirth 2006;6:30.
8. Clausen TD, Mathiesen E, Ekbom P, et al. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 2005;28:323e8.
9. Jungheim ES, Moley KH. Current knowledge of obesity's effects in the pre- and periconceptional periods and avenues for future research. Am J Obstet Gynecol 2010;203:525e30.
10. Davies GA, Maxwell C, McLeod L, et al. Society of Obstetricians and Gynaecologists of Canada. Obesity in pregnancy. J Obstet Gynaecol Can 2010;32:165e73.
11. Watkins ML, Rasmussen SA, Honein MA, et al. Maternal obesity and risk for birth defects. Pediatrics 2003;111:1152e8.
12. Laraia BA, Bodnar LM, Siega-Riz AM. Pregravid body mass index is negatively associated with diet quality during pregnancy. Public Health Nutr 2007;10: 920e6.
13. Centers for Disease Control and Prevention. Folate status in women of childbearing age, by race/ethnicityeUnited States, 1999-2000, 2001-2002, and 2003-2004. MMWR Morb Mortal Wkly Rep 2007;55:1377-80.
14. Ray JG, Wyatt PR, Vermeulen MJ, et al. Greater maternal weight and the ongoing risk of neural tube defects after folic acid flour fortification. Obstet Gynecol 2005;105:261e5.
15. Mojtabai R. Body mass index and serum folate in childbearing age women. Eur J Epidemiol 2004;19:1029e36.
16. American Diabetes Association. Preconception care of women with diabetes (Position Statement). Diabetes Care 2004;27(suppl 1):S76e8.
17. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational diabetes mellitus. Obstet Gynecol 2005;105:675e85.
18. National Collaborating Centre for Women's and Children's Health. Diabetes in pregnancy management of diabetes and its complications from preconception to the postnatal period. RCOG Press at the Royal College of Obstetricians and Gynaecologists, 2008. (available online at http://www.nice.org.uk/nicemedia/live/11946/41320/41320.pdf).
19. Thompson D, Capes S, Feig D, et al. Diabetes and pregnancy. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2008;32:S168e80.
20. Koren G, Goh YI, Klieger C. Folic acid. The right dose. Can Family Physician 2008;54:1545e7.
21. Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. Lancet 2001;358:2069e73.
22. Gutzin SJ, Kozer E, Magee LA, et al. The safety of oral hypoglycemic agents in the first trimester of pregnancy: a meta-analysis. Can J Clin Pharmacol 2003; 10:179e83.
23. Bowen ME, Ray WA, Arbogast PG, et al. Increasing exposure to angiotensinconverting enzyme inhibitors in pregnancy. Am J Obstet Gynecol 2008;198: 291.e1e5.
24. Andrade SE, Raebel MA, Brown J, et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Safety 2008;17:240e7.
25. Pollack PS, Shields KE, Burnett DM, et al. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 2005;73:888e96.
26. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 2008;26:175e7.
27. Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007;29:906e8.
28. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443e51.
29. Diav-Citrin O, Shechtman S, Halberstadt Y, et al. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 2011;31:540e5.
30. Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011;343:d5931.
31. Holing EV, Beyer CS, Brown ZA, Connell FA. Why don't women with diabetes plan their pregnancies?. Diabetes Care 1998;21:889e95.
32. Kim C, Ferrara A, McEwen LN, et al. Preconception care in managed care: the translating research into action for diabetes study. Am J Obstet Gynecol 2005; 192:227e32.
33. Murphy HR, Temple RC, Ball VE, et al. Personal experiences of women with diabetes who do not attend pre-pregnancy care. Diabetic Med 2010;27: 92e100.
34. Endres LK, Sharp LK, Haney E, Dooley SL. Health literacy and pregnancy preparedness in pregestational diabetes. Diabetes Care 2004;27:331e4.
35. Schillinger D, Piette J, Grumbach K, et al. Closing the loop. Physician communication with diabetic patients who have low health literacy. Arch Intern Med 2003;163:83e90.
36. Griffiths F, Lowe P, Boardman F, et al. Becoming pregnant: exploring the perspectives of women living with diabetes. Br J Gen Pract 2008;58: 184e90.
37. Temple R. Preconception care for women with diabetes: is it effective and who should provide it?. Best Pract Res Clin Obstet Gynecol 2011;25:3e14.
38. Murphy HR, Roland JM, Skinner TC, et al. Effectiveness of a regional prepregnancy care program in women with type 1 and type 2 diabetes. Diabetes Care 2010;33:25514e20.